alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350

The undersigned, Wayne P. Garten, President and Chief Executive Officer, and
Charles E. Blue, Senior Vice President and Chief Financial Officer, of Hanover
Direct, Inc. (the "Company"), each hereby certifies that to his knowledge the
Quarterly Report on Form 10-Q for the fiscal quarter ended March 27, 2004 of the
Company filed with the Securities and Exchange Commission on the date hereof
(the "Report") fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934 and the information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company for the period specified.

Signed at the City of Edgewater, in the State of New Jersey, this 11th day of
May, 2004.


                               /s/ Wayne P. Garten
                     -------------------------------------
                                 Wayne P. Garten
                     President and Chief Executive Officer



                               /s/ Charles E. Blue
                     -------------------------------------
                                 Charles E. Blue
                            Senior Vice President and
                             Chief Financial Officer

A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.

                                       37
Exhibit
32.1








CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002








In
connection with the Quarterly Report on Form 10-Q of AFP Imaging Corporation
(the “Company”) for the quarterly period ended December 31, 2008, as filed with
the Securities and Exchange Commission (the “Report”), I, David Vozick, Co-Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:





(1)
            The
      Report fully complies with the requirements of section 13 (a) or 15 (d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.







/s/__ David Vozick
      _____________________David
      VozickChairman
      of the BoardCo-Chief
      Executive Officer





Date:
February 23, 2009
Exhibit 13.2



CERTIFICATION



This certification is provided pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, and accompanies the Annual Report on Form 20-F (the “Report”) for the
period ended December 31, 2016 of Banco Latinoamericano de Comercio Exterior, S.A. (the “Company”).



I, Christopher Schech, the Chief Financial
Officer of the Company, certify that:



| | (i) | The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934, as amended; and
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------



| | (ii) | The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company at the dates and for the periods presented.
| | ---- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Date: April 28, 2017



|By:                     | 
|----------------------- | 
|/s/ Christopher Schech  | 
|Chief Financial Officer |
Fourth Court of Appeals

San Antonio, Texas

JUDGMENT

No. 04-22-00669-CR

Arnoldo A. ALMEIDA,

Appellant

v.

The STATE of Texas,

Appellee

From the 175th Judicial District Court, Bexar County, Texas

Trial Court No. 2021CR7294

Honorable Catherine Torres-Stahl, Judge Presiding

BEFORE JUSTICE RODRIGUEZ, JUSTICE VALENZUELA, AND JUSTICE BRISSETTE

In accordance with this court’s opinion of this date, the trial court’s judgment is 

AFFIRMED.

SIGNED September 11, 2024.

_____________________________

Lori Massey Brissette, Justice
Filed 8 March and 3 May 2007

#### Binney v. Banner Therapy Products, Inc.

Case below: 178 N.C. App. 417

No. 431A06

1. Respondent’s (ESC) NOA Based Upon a Dissent (COA05-916)

2. Respondent’s (ESC) PDR as to Additional Issues

1.-

2. Allowed 03/08/07
<TABLE> <S> <C>

<PAGE>
<ARTICLE> UT
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               JUN-30-1997
<BOOK-VALUE>                                  PER-BOOK
<TOTAL-NET-UTILITY-PLANT>                      184,934
<OTHER-PROPERTY-AND-INVEST>                      1,179
<TOTAL-CURRENT-ASSETS>                          52,400
<TOTAL-DEFERRED-CHARGES>                        12,962
<OTHER-ASSETS>                                       0
<TOTAL-ASSETS>                                 251,475
<COMMON>                                         5,812
<CAPITAL-SURPLUS-PAID-IN>                       56,461
<RETAINED-EARNINGS>                             27,876
<TOTAL-COMMON-STOCKHOLDERS-EQ>                  90,149
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      6,400
<LONG-TERM-DEBT-NET>                            72,812
<SHORT-TERM-NOTES>                              12,890
<LONG-TERM-NOTES-PAYABLE>                       73,875
<COMMERCIAL-PAPER-OBLIGATIONS>                       0
<LONG-TERM-DEBT-CURRENT-PORT>                    2,173
<PREFERRED-STOCK-CURRENT>                            0
<CAPITAL-LEASE-OBLIGATIONS>                      1,586
<LEASES-CURRENT>                                   476
<OTHER-ITEMS-CAPITAL-AND-LIAB>                  66,575
<TOT-CAPITALIZATION-AND-LIAB>                  251,475
<GROSS-OPERATING-REVENUE>                      186,905
<INCOME-TAX-EXPENSE>                             6,133
<OTHER-OPERATING-EXPENSES>                     163,425
<TOTAL-OPERATING-EXPENSES>                     169,558
<OPERATING-INCOME-LOSS>                         17,347
<OTHER-INCOME-NET>                                  13
<INCOME-BEFORE-INTEREST-EXPEN>                  17,360
<TOTAL-INTEREST-EXPENSE>                         5,737
<NET-INCOME>                                    11,623
<PREFERRED-STOCK-DIVIDENDS>                        487
<EARNINGS-AVAILABLE-FOR-COMM>                   11,136
<COMMON-STOCK-DIVIDENDS>                         4,673
<TOTAL-INTEREST-ON-BONDS>                        4,537
<CASH-FLOW-OPERATIONS>                          29,855
<EPS-PRIMARY>                                     1.93
<EPS-DILUTED>                                     1.93
        


</TABLE>
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER 
                      AND CHIEF FINANCIAL OFFICER

Pursuant to 
                       18 U.S.C. Section 1350,
                     as Adopted Pursuant to
                     Section 906 of the Sarbanes-Oxley Act of 2002

Solely for the purposes of complying with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, we the undersigned Chief Executive Officer and Chief Financial Officer of NPS Pharmaceuticals, Inc. certify that the
Annual Report of NPS Pharmaceuticals, Inc. on Form 10-K for the fiscal year ended December 31, 2007 fully complies with the requirements
of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in
all material respects, the financial condition and results of operations of NPS Pharmaceuticals, Inc.



|Date: March 14, 2008 | /s/ N. ANTHONY COLES
                      N. Anthony ColesPresident and Chief Executive Officer
|-------------------- | ------------------------------------------------------------------------------------------------



|Date: March 14, 2008 | /s/ LUKE M. BESHAR
                      Luke M. Beshar Senior Vice President and Chief Financial Officer
|-------------------- | ---------------------------------------------------------------------------------------------------------

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure
document.

A signed original of this written statement required by Section 906 has been provided to NPS Pharmaceuticals, Inc. and will be retained
by NPS Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

---
<TABLE> <S> <C>
 
<ARTICLE>      5 
<LEGEND> THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
         FROM CONDENSED CONSOLIDATED BALANCE SHEETS, CONDENSED
         CONSOLIDATED STATEMENTS OF OPERATIONS AND NOTES TO CONDENSED
         CONSOLIDATED FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS
         ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000 
       
<S>                                              <C>
<PERIOD-TYPE>                                    9-MOS
<FISCAL-YEAR-END>                                DEC-31-1998
<PERIOD-START>                                   JAN-01-1998
<PERIOD-END>                                     OCT-04-1998
<CASH>                                             39,614
<SECURITIES>                                            0
<RECEIVABLES>                                      24,581
<ALLOWANCES>                                          366
<INVENTORY>                                        26,269
<CURRENT-ASSETS>                                  109,646
<PP&E>                                            432,522
<DEPRECIATION>                                    237,504
<TOTAL-ASSETS>                                    314,690
<CURRENT-LIABILITIES>                              49,817
<BONDS>                                           280,000
<PREFERRED-MANDATORY>                                   0
<PREFERRED>                                        25,000
<COMMON>                                              401
<OTHER-SE>                                        (56,598)
<TOTAL-LIABILITY-AND-EQUITY>                      314,690
<SALES>                                           150,637
<TOTAL-REVENUES>                                  150,637
<CGS>                                             123,711
<TOTAL-COSTS>                                     123,711
<OTHER-EXPENSES>                                   22,155
<LOSS-PROVISION>                                      150
<INTEREST-EXPENSE>                                 17,323
<INCOME-PRETAX>                                   (83,422)
<INCOME-TAX>                                      (13,016)
<INCOME-CONTINUING>                               (70,406)
<DISCONTINUED>                                          0
<EXTRAORDINARY>                                         0
<CHANGES>                                               0
<NET-INCOME>                                      (70,406)
<EPS-PRIMARY>                                        0.00
<EPS-DILUTED>                                        0.00

         

</TABLE>
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               JAN-30-1996
<CASH>                                           2,497
<SECURITIES>                                         0
<RECEIVABLES>                                    1,343
<ALLOWANCES>                                       320
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 3,662
<PP&E>                                          11,963
<DEPRECIATION>                                   4,599
<TOTAL-ASSETS>                                  11,772
<CURRENT-LIABILITIES>                            2,402
<BONDS>                                              0
<PREFERRED-MANDATORY>                           70,996
<PREFERRED>                                        471
<COMMON>                                           290
<OTHER-SE>                                    (62,387)
<TOTAL-LIABILITY-AND-EQUITY>                    11,772
<SALES>                                          2,327
<TOTAL-REVENUES>                                10,046<F1>
<CGS>                                            1,083
<TOTAL-COSTS>                                    1,083
<OTHER-EXPENSES>                                 1,714
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 187
<INCOME-PRETAX>                                  7,062<F1>
<INCOME-TAX>                                       127
<INCOME-CONTINUING>                              6,935
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  1,831
<CHANGES>                                            0
<NET-INCOME>                                     (626)
<EPS-PRIMARY>                                   (0.03)
<EPS-DILUTED>                                   (0.03)
<FN>
<F1>Includes $7,100 of net litigation settlement gain, a non-recurring item.
</FN>
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                          37,192
<SECURITIES>                                         0
<RECEIVABLES>                                   18,882
<ALLOWANCES>                                     1,206
<INVENTORY>                                          0
<CURRENT-ASSETS>                                58,279
<PP&E>                                         569,623
<DEPRECIATION>                                 173,665
<TOTAL-ASSETS>                                 462,660
<CURRENT-LIABILITIES>                           29,262
<BONDS>                                        249,311
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        16,508
<OTHER-SE>                                     128,470
<TOTAL-LIABILITY-AND-EQUITY>                   462,660
<SALES>                                              0
<TOTAL-REVENUES>                                61,428
<CGS>                                                0
<TOTAL-COSTS>                                   77,312
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   150
<INTEREST-EXPENSE>                              12,010
<INCOME-PRETAX>                               (30,359)
<INCOME-TAX>                                   (9,053)
<INCOME-CONTINUING>                           (21,306)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  (420)
<CHANGES>                                            0
<NET-INCOME>                                  (21,726)
<EPS-BASIC>                                     (0.13)
<EPS-DILUTED>                                   (0.13)


</TABLE>
MINNEAPOLIS, MN, July 23, 2013 –
         
   Uroplasty will release financial results for the fiscal first quarter ended June 30, 2013 at the market close on August 1, 2013.  The Company will host a conference call and webcast to discuss these results on August 1, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time).  Individuals wishing to participate in the conference call should dial 877-941-2333.  No passcode is necessary.  To access the live webcast of the call, go to Uroplasty’s website at www.uroplasty.com and click on the Investor Relations section. An archived webcast will also be available at investor.uroplasty.com.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONDENSED STATEMENTS OF ASSETS, LIABILITIES AND TRUST CORPUS OF SAN
JUAN BASIN ROYALTY TRUST AS OF SEPTEMBER 30, 2000, AND THE RELATED CONDENSED
STATEMENTS OF DISTRIBUTABLE INCOME AND CHANGES IN TRUST CORPUS FOR THE
NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2000.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       7,391,680
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             7,391,680
<PP&E>                                     133,275,528
<DEPRECIATION>                              91,616,394
<TOTAL-ASSETS>                              49,050,814
<CURRENT-LIABILITIES>                        7,391,680
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  41,659,134
<TOTAL-LIABILITY-AND-EQUITY>                49,050,814
<SALES>                                              0
<TOTAL-REVENUES>                            43,535,327
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               802,537
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                             42,732,790
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         42,732,790
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                42,732,790
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
EXHIBIT 31.1

 

**CERTIFICATIONS**

I, Wayne P. Garten, certify that: 

 
| 1. | I have reviewed this quarterly report on Form 10-Q of Hanover Direct, Inc.; |
|----|-----------------------------------------------------------------------------|

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and have:

 

a.      Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.      Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

c.      Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a.      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
|  

 

/s/ Wayne P. Garten

Wayne P. Garten

President and Chief Executive Officer

 

 

  |
|---------------------------------------------------------------------------------------------------------------------|

Date: February 21, 2006
EX-35.3
(logo) WELLS FARGO

Corporate Trust Services
MAC N2702-011
9062 Old Annapolis Road
Columbia, MD 21045
410 884-2000
410 715-2380 Fax

Wells Fargo Bank, N.A.

Structured Asset Mortgage Investments II Inc.
383 Madison Avenue
New York, NY 10179


RE: Annual Statement as to Compliance


The undersigned, a duly authorized officer of Wells Fargo Bank, N.A. ("Wells
Fargo"), hereby certifies as follows for the calendar year 2008:

(a) a review of Wells Fargo's activities as Trustee under the servicing
agreement(s) listed on Schedule A hereto (the "Servicing Agreement(s)") has been
made under my supervision; and

(b) to the best of my knowledge, based on such review Wells Fargo has fulfilled
all of its obligations under the Servicing Agreement(s) in all material respects
throughout the reporting period.

February 24, 2009

/s/ Melissa Loiselle

MELISSA LOISELLE
Vice President


(page)


(logo) WELLS FARGO

Corporate Trust Services
MAC N2702-011
9062 Old Annapolis Road
Columbia, MD 21045
410 884-2000
410 715-2380 Fax

Wells Fargo Bank, N.A.

To: Structured Asset Mortgage Investments II Inc.

Schedule A

List of Servicing Agreement(s) and Series

1 Pooling Agreement for Bear Stearns Structured Products Inc. Trust, Series
2008-R1, Wells Fargo Bank, N.A. as Trustee

2 Pooling and Servicing Agreement for Bear Stearns ARM Trust, Mortgage
Pass-Through Certificates Series 2007-3, Wells Fargo Bank, N.A. as Trustee